Last reviewed · How we verify
Janssen Ad26.COV2.S
At a glance
| Generic name | Janssen Ad26.COV2.S |
|---|---|
| Also known as | Janssen |
| Sponsor | Alvea Holdings, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients (PHASE3)
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders (PHASE2)
- Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen (PHASE4)
- Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
- Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Janssen Ad26.COV2.S CI brief — competitive landscape report
- Janssen Ad26.COV2.S updates RSS · CI watch RSS
- Alvea Holdings, LLC portfolio CI